Intravenous microemulsion of docetaxel containing an anti-tumor synergistic ingredient (Brucea javanica oil): Formulation and pharmacokinetics

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 4045-4052

  Ma, Shilin ^a   Chen, Fen ^a   Ye, Xiaohui ^b   Dong, Yingjie ^b   Xue, Yingna ^a   Xu, Heming ^a   Zhang, Wenji ^a   Song, Shuangshuang ^a   Ai, Li ^b   Zhang, Naixian ^b   Pan, Weisan ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b Liaoning Institute of Pharmaceutical Industry   (China)

Author keywords

Docetaxel; Formulation; Microemulsion; Pharmacokinetic; Synergistic ingredient

Indexed keywords

DOCETAXEL; LINOLEIC ACID; MACROGOL 400; OLEIC ACID; PHOSPHATIDYLCHOLINE; SOLUTOL HS 15; TRIACYLGLYCEROL; WATER;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MIXTURE; DRUG POTENTIATION; MALE; MICROEMULSION; MONOTHERAPY; NONHUMAN; PARTICLE SIZE; PHAGOCYTOSIS; RAT; REACTION OPTIMIZATION; RETICULOENDOTHELIAL SYSTEM; SINGLE DRUG DOSE; VISCOSITY; ZETA POTENTIAL;

DOCETAXEL; FORMULATION; MICROEMULSION; PHARMACOKINETIC; SYNERGISTIC INGREDIENT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRUCEA; CAPSULES; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; DRUG SYNERGISM; EMULSIONS; HUMANS; INJECTIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; PARTICLE SIZE; PLANT OILS; RATS; RATS, SPRAGUE-DAWLEY; TAXOIDS; TREATMENT OUTCOME;

EID: 84886694579     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S47956     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: Cancer J Clin. 2011;61(2):69-90.
2. Moes JJ, Koolen SL, Huitema AD, Schellens JHM, Beijnen JH, Nuijen B. Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001). Int J Pharm. 2011;420(2):244-250.
3. Herbst RS, Khuri FR, Lu C, et al. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma. Cancer. 2002;95(2):340-353.
4. Guéritte-Voegelein F, Guénard D, Lavelle F, Le Goff MT, Mangatal L, Poitier P. Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem. 1991;34(3):992-998.
5. Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere): a semisynthetic analog of taxol. J Natl Cancer Inst. 1991;83(4):288-291.
6. Hong WK. The current status of docetaxel in solid tumors. An MD Anderson Cancer Center Review. Oncology (Williston Park). 2002;16(Suppl 6):9-15.
7. Van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs. 2001;19(2):125-141.
8. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37(13):1590-1598.
9. Alexopoulos A, Karamouzis MV, Stavrinides H, et al. Phase II study of pegylated liposomal doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer. Ann Oncol. 2004;15(6): 891-895.
10. Immordino ML, Brusa P, Arpicco S, Stella B, Dosio F, Cattel L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J Control Release. 2003;91(3): 417-429.
11. Chan JM, Zhang L, Yuet KP, et al. PLGA lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials. 2009;30(8): 1627-1634.
12. Hwang HY, Kim IS, Kwon IC, Kim YH. Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles. J Control Release. 2008;128(1):23-31.
13. Liu B, Yang M, Li R, et al. The antitumor effect of novel docetaxel-loaded thermosensitive micelle. Eur J Pharm Biopharm. 2008;69(2): 527-534.
14. Lee E, Kim H, Lee IH, Jon SY. In vivo antitumor effects of chitosan-conjugated docetaxel after oral administration. J Control Release. 2009;140(2):79-85.
15. Esmaeili F, Dinarvand R, Ghahremani MH, et al. Docetaxel-albumin conjugates: preparation, in vitro evaluation and biodistribution studies. J Pharm Sci. 2009;98(8):2718-2730.
16. Grosse PY, Bressolle F, Pinguet F. In vitro modulation of doxorubicin and docetaxel antitumoral activity by methyl-β-cyclodextrin. Eur J Cancer. 1998;34(1):168-174.
17. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev. 2000;45(1):89-121.
18. Eccleston GM. Emulsions and microemulsions. In: Swarbrick J. Encyclopedia of pharmaceutical technology. New York: Informa Healthcare USA. 2007:1561-1565.
19. Park JH, Lee S, Kim JH, Park K, Kim K, Kwon IC. Polymeric nanomedicine for cancer therapy. Prog Polym Sci. 2008;33(1):113-137.
20. Su BN, Chang LC, Park EJ, et al. Bioactive constituents of the seed of Brucea javanica. Planta med. 2002;68(8):730-733.
21. Nie YL, Liu KX, Mao XY, Li YL, Li J, Zhang MM. Effect of injection of brucea javanica oil emulsion plus chemoradiotherapy for lung cancer: a review of clinical evidence. J Evid Based Med. 2012;5(4):216-225.
22. Liu Y, Wang H, FU Q. An experimental study of Brucea javanica oil emulsion on bladder carcinoma. Chin J Urol. 2001:336-338.
23. Lou GG, Yao HP, Xie LP. Brucea javanica oil induces apoptosis in T24 bladder cancer cells via upregulation of caspase-3, caspase-9, and inhibition of NF-kappaB and COX-2 expressions. Am J Chin Med. 2010;38(3):613-624.
24. Cai WH, Deng WD, Yang HH, Chen XP, Jin F. A propofol microemulsion with low free propofol in the aqueous phase: formulation, physicochemical characterization, stability and pharmacokinetics. Int J Pharm. 2012;436(1-2):536-544.
25. Zhao X, Chen D, Gao P, Ding P, Li K. Synthesis of ibuprofen eugenol ester and its microemulsion formulation for parenteral delivery. Chem Pharm Bull (Tokyo). 2005;53(10):1246-1250.
26. Zhuang CY, Li N, Wang M, et al. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm. 2010;394(1-2):179-185.
27. Zheng X, Kan B, Gou M, et al. Preparation of MPEG-PLA nanoparticle for honokiol delivery in vitro. Int J Pharm. 2010;386(1):262-267.
28. Zhao L, Wientjes MG, Au JL. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res. 2004;10(23): 7994-8004.
29. Bhargava HN, Narurkar A, Lieb LM. Using microemulsions for drug delivery. Pharm Tech. 1987;11(3):46-52.
30. Lawrence MJ. Surfactant systems: microemulsions and vesicles as vehicles for drug delivery. Eur J Drug Metab Pharmacokinet. 1994; 19(3):257-269.
31. Tenjarla S. Microemulsions: an overview and pharmaceutical applications. Crit Rev Ther Drug Carrier Syst. 1999;16(5):461-521.
32. Ghosh PK, Murthy RSR. Microemulsions: a potential drug delivery system. Curr Drug Deliv. 2006;3(2):167-180.
33. Aboofazeli R, Lawrence CB, Wicks SR, Lawrence MJ. Investigations into the formation and characterization of phospholipid microemulsions. III. Pseudo-ternary phase diagrams of systems containing water-lecithin-isopropyl myristate and either an alkanoic acid, amine, alkanediol, polyethylene glycol alkyl ether or alcohol as cosurfactant. Int J Pharm. 1994;111(1):63-72.
34. Stilbs P, Rapacki K, Lindman B. Effect of alcohol cosurfactant length on microemulsion structure. J Colloid Interface Sci. 1983;95(2): 583-585.
35. Coon JS, Knudson W, Clodfelter K, Lu B, Weinstein RS. Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance. Cancer Res. 1991;51(3):897-902.
36. Woodcock DM, Linsenmeyer ME, Chojnowski G, et al. Reversal of multidrug resistance by surfactants. Br J Cancer. 1992;66(1):62-68.
37. Buckingham LE, Balasubramanian M, Emanuele RM, Clodfelter KE, Coon JS. Comparison of solutol HS 15, Cremophor EL and novel ethoxylated fatty acid surfactants as multidrug resistance modification agents. Int J Cancer. 1995;62(4):436-442.
38. Talegaonkar S, Azeem A, Ahmad FJ, Khar RK, Pathan SA, Khan ZI. Microemulsions: a novel approach to enhanced drug delivery. Recent Pat Drug Deliv Formul. 2008;2(3):238-257.
39. Zhao M, Su M, Lin X, et al. Evaluation of docetaxel-loaded intravenous lipid emulsion: pharmacokinetics, tissue distribution, antitumor activity, safety and toxicity. Pharm Res. 2010;27(8):1687-1702.